Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study

[1] Calverley PM(2007)Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 775-789

[2] Anderson JA(2008)Methodological issues in therapeutic trials of COPD Eur Respir J 31 927-933

[3] Celli B(2009)Inhaled corticosteroids in COPD: the case against Eur Respir J 34 13-16

[4] Ferguson GT(2008)Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study Can Respir J 15 13-19

[5] Jenkins C(2016)Indacaterol–glycopyrronium versus Salmeterol–fluticasone for COPD N Engl J Med 374 2222-2234

[6] Jones PW(2014)Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective Br J Clin Pharmacol 78 282-300

[7] Yates JC(2011)Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society Ann Intern Med 155 179-191

[8] Vestbo J(2008)The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 19-26

[9] Suissa S(2009)Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Eur Respir J 34 641-647

[10] Ernst P(2011)Reported pneumonia in patients with COPD: findings from the INSPIRE study Chest 139 505-512

[1] Calverley PM(2007)Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 775-789

[2] Anderson JA(2008)Methodological issues in therapeutic trials of COPD Eur Respir J 31 927-933

[3] Celli B(2009)Inhaled corticosteroids in COPD: the case against Eur Respir J 34 13-16

[4] Ferguson GT(2008)Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study Can Respir J 15 13-19

[5] Jenkins C(2016)Indacaterol–glycopyrronium versus Salmeterol–fluticasone for COPD N Engl J Med 374 2222-2234

[6] Jones PW(2014)Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective Br J Clin Pharmacol 78 282-300

[7] Yates JC(2011)Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society Ann Intern Med 155 179-191

[8] Vestbo J(2008)The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 19-26

[9] Suissa S(2009)Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Eur Respir J 34 641-647

[10] Ernst P(2011)Reported pneumonia in patients with COPD: findings from the INSPIRE study Chest 139 505-512